Is SRx Health Solutions, Inc. overvalued or undervalued?

As of 11 August 2025, the valuation grade for SRx Health Solutions, Inc. moved from fair to attractive, indicating a more favorable assessment of its value. The company appears to be undervalued, especially when considering its P/E ratio of -2.6224 and EV to EBITDA of -2.6667, which are significantly lower than typical industry metrics.
In comparison to peers, SRx Health Solutions stands out with its negative P/E ratio, while other companies in the pharmaceuticals and biotechnology sector may show more robust valuations. Despite the attractive grade, the company has faced substantial declines in stock performance, with a year-to-date return of -85.57% compared to the S&P 500's 12.22%, highlighting the challenges it faces in the market.